MedDataX Logo

Haptoglobin and Iron in Parkinson's Disease

NCT ID: NCT02422992

Last Updated: 2016-11-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

342 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-02-28

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a case/control epidemiology study to identify what are the iron-metabolism abnormalities in Parkinson's disease (PD) patients, and risk factors relevant to PD predisposition.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A total of 342 participants, 100 PD patients and 242 age- and gender matched controls, were included in the study. All study participants were seen for one study visit in the morning at one of two Bastyr University Clinics in the Seattle area. Study participants were fasting at the time of the visit. During the study visit, participants donated a blood sample for the blood tests and complete an epidemiology questionnaire.

A subset of 51 of the study participant who were seen for the visit at Bastyr University, underwent brain scan and Magnetic Resonance Imaging (MRI), at the University of Washington Department of Radiology. The MRI part of the study aims at estimating brain iron levels.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Iron metabolism MRI risk factors haptoglobin phenotype

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PD

100 PD patients were patients diagnosed with Parkinson's disease

No interventions assigned to this group

Controls

242 Controls were subjects free of neurodegenerative diseases, matched by age and gender to the PD patients

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Volunteers should be of age between 52 and 82 years of age, males of females.


Diagnosis of Parkinson's disease (UKBB clinical criteria).

Exclusion Criteria

* presence of a neurodegenerative disease,
* presence of active cancer under treatment,
* HIV sero-positivity, Hepatitis B, C, of A sero-positivity
* rheumatoid arthritis
* recent blood donation (less than three months before the visit).
* fever at the time of the visit


* Presence of other neurodegenerative diseases, apart for Parkinson's disease
* two or more family members with Parkinson's disease
* presence of active cancer under treatment
* HIV sero-positivity, Hepatitis B, C, of A sero-positivity
* rheumatoid arthritis
* recent blood donation (less than three months before the visit).
* fever at the time of the visit


* presence in the body of a ferro-magnetic metallic foreign object such as, but not limited to:
* a cardiac pacemaker
* aneurism clip
* neuro-stimulator
* surgical clip
* artificial limb or joint
* orthopedic items, such as screws, nails, pins, rods,
* any metallic foreign body from a previous injury, bullets, shrapnels, metal slivers.
Minimum Eligible Age

35 Years

Maximum Eligible Age

92 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Washington

OTHER

Sponsor Role collaborator

Bastyr University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Paola Costa-Mallen, PhD

Role: PRINCIPAL_INVESTIGATOR

Bastyr University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of California

San Diego, California, United States

Site Status

Bastyr University Research Institute

Kenmore, Washington, United States

Site Status

University of Washington

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Costa-Mallen P, Checkoway H, Zabeti A, Edenfield MJ, Swanson PD, Longstreth WT Jr, Franklin GM, Smith-Weller T, Sadrzadeh SM. The functional polymorphism of the hemoglobin-binding protein haptoglobin influences susceptibility to idiopathic Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet. 2008 Mar 5;147B(2):216-22. doi: 10.1002/ajmg.b.30593.

Reference Type BACKGROUND
PMID: 17918239 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

12A-1330

Identifier Type: -

Identifier Source: org_study_id